comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 17:22:28 - browse：75

A hand in pink glove holds a blue rack that contains three tubes of blood samples — first opinion coverage from STAT — Joe Raedle/Getty Images

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

But look closer, and you’ll see that these grand promises often fall apart when sponsors implement complicated plans for collecting blood, tissue and other biospecimens and impossible processes for managing those samples. Behind all the talk and regulatory guidance, there’s a reluctance to change how these essential elements of clinical trial execution are handled, putting the very ideals that sponsors are trying to uphold at risk.

The concept of site and patient centricity frequently gets reduced to addressing only superficial gestures, such as committing to promptly paying sites for their work or using tablets for conducting patient surveys. But the essence of centricity extends far beyond these surface-level measures. It lies in addressing the unseen and unmentioned complexities of clinical trials and providing real solutions that focus on truly prioritizing the needs of trial sites and participants.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Time to name cancers by genetics, not organ of origin, expert says

WSS

What we need to know about Arena Bioworks

The world needs the new pandemic treaty

J&J reports mixed data on next

Hospitals need to get ahead of regulations on climate change

ARCH Venture Partners is raising $3 billion for a life sciences fund

Novo Nordisk to expand supply of Wegovy for U.S. patients

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Quicker fix for pulse oximeters urged during FDA public meeting

ChatGPT in medicine: STAT answers readers' burning questions

Hospitals need to get ahead of regulations on climate change

DIEP, the 'gold standard' of breast reconstruction, is under threat

Novo Nordisk to expand supply of Wegovy for U.S. patients

Virginia high school admissions case could be legal follow

Why we need mandatory labeling of GMO products

Continuity nursing helped my family in our darkest PICU moments

Quicker fix for pulse oximeters urged during FDA public meeting

leisure time

FDA drug safety: Singulair case shows systemic surveillance flaws

A $475,000 price tag for a new cancer drug: crazy or meh?

Ozempic cut risk of death in diabetes patients with chronic kidney disease

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Why some fertility treatments produce more boy babies

Unmasking the 'centricity' illusion in clinical trials

knowledge

hotspot

knowledge

hotspot